We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the top 1% most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

The nervous system is commonly involved by SLE. Its involvement classified as primary when it is related to the disease process and secondary when it is related to other factors like medication side effect or infection. The nervous system involvement by lupus was described by Hebra and Kaposi in 1875 who described a patient with lupus and coma (Appenzeller et al., 2006). Shortly after Bowen report case of psychosis and mood disturbance (Appenzeller et al., 2006).

The nervous system involvement rang from overt presentation to more subtle finding. In spite the advances in SLE diagnosis and managements, the neuropsychiatric syndromes remain one of the major causes of morbidity and mortality in SLE patients. Still they remain poorly understood and under recognised. The aim of this chapter is provide an overview of neurological presentation in SLE patients.

2. Definition

As there is wide Varity of different neurological and psychiatric presentations among SLE patient, the American college of Rheumatology (ACR) established in 1999 19 different neuropsychiatric SLE (NPSLE) syndromes (table-1). Either central or peripheral nervous system can be affected by the disease process. Their involvement can be generalized e.g. headache, cognitive dysfunction or focal e.g. cerebrovascular disease and demyelinating syndromes.

Before attributing any of the neuropsychiatric (NP) manifestation to SLE secondary causes should be ruled out. As most of SLE patient are immunocompromised either by the disease process or secondary to immunocompressive therapy infection is a common problem in this patients. Other secondary causes can be metabolic impairments or complication from hypertension e.g. posterior reversible leukoencephalopathy.

3. Epidemiology

The reported prevalence of NPSLE is varied from 37- 95 % (Muscal & Brey, 2010) depending on the case definition used and the inclusion criteria. Most of NPSLE affect central nervous system (91.6%) and out of those 79% are diffuse in nature and 21% focal (Hanly et al., 2008). The peripheral nervous system involvement is much less than CNS involvement.
<table>
<thead>
<tr>
<th>NPSLE Associated with Central Nervous System</th>
<th>NPSL Associated with Peripheral Nervous System</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Aseptic Meningitis</td>
<td>- Acute Inflammatory</td>
</tr>
<tr>
<td>- Cerebrovascular disease</td>
<td>- Demyelinating Syndromes (Gulliain-Barre Syndrome)</td>
</tr>
<tr>
<td>- Demyelinating syndromes</td>
<td>- Autonomic Neuropathy</td>
</tr>
<tr>
<td>- Headaches</td>
<td>- Mononeuropathy, single or multiplex</td>
</tr>
<tr>
<td>- Movement Disorders (Chorea)</td>
<td>- Myasthenia Gravis</td>
</tr>
<tr>
<td>- Myelopathy</td>
<td>- Cranial Neuropathy</td>
</tr>
<tr>
<td>- Seizure Disorders</td>
<td>- Plexopathy</td>
</tr>
<tr>
<td>- Acute Confusional State</td>
<td>- Polyneuropathy</td>
</tr>
<tr>
<td>- Anxiety Disorders</td>
<td></td>
</tr>
<tr>
<td>- Cognitive Dysfunction</td>
<td></td>
</tr>
<tr>
<td>- Mood Disorders</td>
<td></td>
</tr>
<tr>
<td>- Psychosis</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Neuropsychiatric Syndromes Associated with SLE

The most frequently reported PNS involvement is peripheral neuropathy between 2.4 to 7% (Hanly et al., 2010) (Ainiala et al., 2001). Recently Hanly and his colleague conducted a large cohort of SLE patients. They reported around 40.3% of SLE patient had at least one NP event and 17.4% had recurrent events (Hanly et al., 2010). The most frequent NP was headache 47.1% followed by mood disorders in 16.5%, Seizure in this cohort reported in 7.5% and cognitive dysfunction in 5.1%.

In other studies when a mild cognitive impairment and mild mood disorders were included higher prevalence of NPSLE is 80-91% (Ainiala et al., 2001) (Brey et al., 2002). When formal neuropsychiatric evaluation is used cognitive dysfunction is reported in 80% of the patient (Ainiala et al., 2001) (Brey et al., 2002). In 70% of those are classified as mild cognitive impairment with impairment of one or two cognitive domains (Ainiala et al., 2001).

The reported prevalence of cerebrovascular accident range between 4.7 to 15% (Hanly et al., 2010) (Ainiala et al., 2001). The prevalence of other NPSLE syndromes is much less with reported prevalence of demyelinating syndrome and movement disorder of 1%. CNS manifestations present as an initial feature of SLE in 24% of cases (Joseph et al., 2007). In general around 50-60% of NPSLE occurred at disease onset or within the first year after SLE onset.

3.1 Risk factors
Risk factors associated with CNS involvements are:
2. Prior history or concurrent NPSLE.
3. Presence of antiphospholipid antibodies especially for focal CNS lesions and seizure (The European League Against Rheumatism EULAR, 2010). It was also noted that patients with APS who had a history of two or more abortion are six times more likely to have CNS events (Karassa et al., 2000).

In term of SLE disease activity two studies have shown that skin lesions are the most frequent lesions associated with CNS disease (EULAR, 2010) (Karassa et al., 2000). Two
Approach to Patients with SLE Presenting with Neurological Findings

studies have shown a protective effect of arthritis to CNS disease ((EULAR, 2010). This was not consistent in other study where arthritis was a second common manifestation after skin disease (Joseph et al.,2007).

4. Pathogenesis

The neuropsychiatric lupus has different manifestations. As the manifestations can be generalized or focal no single pathophysiological mechanism has been implicated in its pathogenesis. Different mechanisms are thought to affect the nervous system and caused the development of NPSLE. Those different mechanisms include vasculopathy, autoantibodie and cytokines.

4.1 Vasculopathy

Vascular occlusion is universally reported in autopsy cases in patient with lupus. Although vasculitis is thought to be the cause of small vessels disease in lupus patient, its occurrence is rare. The most frequent cause is found to be a non inflammatory vasculopathy. On pathology multiple microinfracts, cortical atrophy, gross infracts were seen on the brain. Microhemorrhages are common in NPSLE. Larger haemorrhages like intracerebral are rare. The most common vascular pathology is noninflammatory lesions characterized by endothelial proliferation, intimal fibrosis and lymphocytic infiltration. It may associated by thrombosis (Ellison et al.,1993).

The pathogenesis of the vascular injury initially thought to be secondary to immune complex deposition but now it thought to be secondary to complement activation (Muscal & Brey, 2010).

4.2 Autoantibodies

Autoantibodies play a major role for the development of different manifestations of SLE. Different antibodies have been reported in association with NPSLE. Among those the most frequent antibodies are antiphospholipid (APL) and antiribosomal abs. Antiphospholipid antibodies that includes lupus anticoagulant, anti cardiolipin and anti-beta2 glycoprotein I antibodies are groups of antibodies which target the phospholipid binding plasma proteins such as beta 2 glycoprotein I and prothrombin. As they alter the expression and secretion of procoagulant on the cell surface they subsequently prompt thrombosis.

Their presences were associated with recurrent thrombosis and fatal losses. Multiple neurological presentations are linked to their presence in patient with and without SLE. It associated in particular with focal neurological events like stroke. They also have linked to seizure, movement disorders, cognitive impairment and myelitis.

A subset of anti- DNA antibodies were found to react with NR2 glutamate receptors. Glutamate is an exiatatory neurotransmitter in the brain. It react with NMDA( N-methyl-D-aspartate) receptors which is present throughout the brain tissue. NMDARS that containing NR2A andNR2B are more expressed in CA1 region of the hippocampus and the amygdale. Excessive stimulation of NMDARS results into excessive influx of calcium into the neuronal tissue causing mitochondrial stress and subsequent neuronal death (Aranow et al, 2010).

In animal models anti NR2 receptors antibodies did not cause brain damage in the presence of intact blood brain barrier (BBB). When BBB compromised using bacterial
lipopolysaccharide (LPS) damage to hippocampal neurons took place with no evidence of inflammation. Those mice performed badly on memory function (Kowal et al, 2004). When epinephrine is used to compromise the BBB the hippocampus of those mice was normal but the antibodies react with neurons of the amygdale. Those mice had impaired fear response (Huerta et al., 2006).

Studies have shown a correlation between the CSF anti-NR2 level with diffuse NPSLE not with focal NPSLE (Arinuma et al, 2008) and no relation to serum anti-NR2 level. This may implicate intrathecal production of anti-NR2 antibodies or migration of antibodies through compromised BBB.

Anti-ribosomal P antibodies was reported in association with SLE. Their presence was linked to lupus related Psychosis and depression.

4.3 Cytokine effects
Elevated level of interleukin (IL-1), IL-2, IL-6, IL-8, and interferon gamma (IFNγ) were found in the CSF of patient with NPSLE (Rhiannon, 2007) (Chandy et al., 2008). Also elevated level of tumour necrosis factor (TNF) family ligands BAFF (B-cell activating factor of TNF family) and APRIL (a proliferation-inducing ligand) were seen in CSF of SLE patients. However the level of APRIL was higher in NPSLE patients when compared to SLE patient without NP (Chandy et al, 2008).

The cytokines are thought to be produced locally by the infiltrating immune cells or by the glial cells or the neurons. Different cytokines had different effects. Their role in the pathogenesis of NPSLE is related to stimulating antibodies productions, effecting neurotransmitter release and the release of corticotrophin releasing hormone (CRH). The stimulation of glucocorticoid production results in persistent elevation of glucocorticoid that plays a role in hippocampal atrophy.

5. Approach
A careful evaluation of SLE patients presenting with new neurological symptoms and signs is needed to rule out secondary causes before attributing it to SLE. Different secondary causes can be a cause for neurological symptoms in SLE patients. The management will be different if the presentation related to lupus or to other causes.

The evaluation of SLE patients presenting with neurological symptoms and signs will be the same as non SLE patients. This includes careful clinical, laboratory and imaging studies. The diagnosis of NPSLE is a diagnosis by exclusion. No single laboratory or imaging study will confirm that the neurological presentation is caused by SLE itself. The presence of other lupus related activity could support the diagnosis of NPSLE.

5.1 History
Detailed history is mandatory when evaluating lupus patient presenting with new neurological presentation. Detailed description of the neurological symptoms is necessary to assist for localization and identifying a potential cause for the problem. The onset of the symptoms will help identifying problems with acute versus more chronic disorder. The severity of the presentation and associated other neurological symptoms will help in determine the nature and will assist further regarding the management plan. The presence of fever may suggest the presence of infection.
Detailed SLE history regarding time of diagnosis, disease course, previous neurological presentation and complications related to disease are particularly important. Most of NPSLE present at time of generalized disease activity. Patients with prior neurological involvement are also at higher risk to have recurrence or development of other neurological disorders. Neurological complications can be also developed secondary to other organ involvement by lupus for example acute stroke can be a presentation of libman Sacks endocarditis, or in other example patient may develop posterior reversible leukoencephalopathy (PRES) secondary to hypertension which can be secondary to renal disease in lupus patient. Detailed drug history is important as patient may develop complication related to therapy like psychosis from steroid therapy. Patient on immunosuppressive treatment are immunocompromised so they are at high risk of development of bacterial, viral and fungal infections. Subacute neurological symptom in SLE patient may represent JC virus infection that causes progressive multifocal leukoencephalopathy (PML). PML is a demyelinating disease that mainly reported with HIV patients. Multiple cases of PML also reported in SLE patient either on or not on immunosuppressive therapy (Molloy & Calbrese, 2009). The possibility of infection should be ruled out before attributing a neurological presentation to SLE and starting aggressive immunosuppressive therapy.

Other medication history might be the cause for the neurological presentation. In particular antipsychotic therapy as they can induce movement disorders. The management in that instance will necessitate medication changes rather than immunosuppression. Detailed family history of same problem or other neurological disorders may point to genetically related neurological diagnosis not necessary attributing it to SLE.

When patient present acutely with symptoms and signs suggestive of acute stroke a quick assessment is necessary not to delay thrombolytic therapy if indicated (further discussion regarding cerebrovascular disease is discussed below).

In patient presenting with seizure careful history to characterize the seizure whether it is generalized or focal. The presence of focal seizure could represent structural lesion as a cause of the seizure. Careful medication and systemic review is mandatory as the seizure can be secondary to metabolic abnormalities e.g. uremia or medication induced seizure. The presence of other associated neurological symptoms could point to other possible causes of seizure. In particular the presence of headache, disturb conscious level could be related to posterior reversible leukoencephalopathy, limbic encephalitis or viral encephalitis. The presence of other focal neurological deficit can point to structural lesions such as stroke. One should exclude other non lupus related causes of seizure such as head trauma or genetically determent epilepsy.

5.2 Examination
The aim of the examination is to localize the neurological presentation and reach a possible diagnosis which will be supported by the laboratory investigations.

Careful systemic as well neurological examinations are required when dealing with SLE patients with neurological presentation. In particularly patient need to checked for fever, and had blood pressure measurements. The presence of other area of vascular occlusion could point to vascular cause of the neurological events.

In patient presenting with cognitive problem full neuropsychological assessment should be carried out. That will include assessing simple attention, complex attention, memory, visuospatial processing, language, reasoning/problem solving, psychomotor speed and executive functions.
5.3 Laboratory examination
Full laboratory assessment to rule out infection and metabolic abnormality that could be the cause for the neurological events. That will include complete blood count, electrolytes, kidney and liver function test. Cerebrospinal fluid assessment is necessary in certain cases to rule out infection or other unrelated condition. In patient with subacute presentation and demyelination on imaging the CSF should be sent for JC virus PCR. The CSF level of autoantibodies and inflammatory mediators are not recommended now as it still a research interest.

5.4 Supplementary tests
EEG is indicated in patient presenting with seizure or in patient with acute confusional state. For patient with seizure the EEG will help in determine the subset of patients who are at high risk of seizure recurrence. The most frequent EEG abnormalities reported in SLE patient is bitemporal slowing in 65% of patients (Lampropoulos et al., 2005). Nerve conduction study and electromyography is indicated in patient presenting with peripheral nervous system related complaints.

5.5 Imaging
In acute setting in patient presenting with acute onset neurological events computerized tomography (CT) brain is the imaging modality of choice to rule out haemorrhage. It is also an easily accessible and widely available. The use of CT brain initially will be important to identify a subset of patients who may need thrombolytic therapy. MRI (magnetic resonance imaging) is a preferred imaging modality to evaluate lupus patients with neurological symptoms. It is more sensitive than CT in detecting anatomical abnormalities and determines the extent of disease process. The most frequent abnormalities in MRI is hyperintense white matter lesions which is seen in 70% of patients (Appenzeller et al., 2007). Their presence have been linked to the presence of Apl. Cerebral atrophy is seen in 6-12% in SLE patients (Huizinga et al., 2001)(Appenzeller et al., 2005-2007). Other advanced imaging technique may be of value in assessing patients with NPSLE although there clinical uses are not widely available. Those includes MTR (magnetization transfer ratio), diffusion weighted images, MRS (magnetic resonance spectroscopy), functional MRI and single photon emission computed tomography.

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Laboratory</th>
<th>CSF</th>
<th>Imaging</th>
<th>Electrophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CBC, Electrolytes, Kidney and liver function</td>
<td>WBC, Glucose, protein, Gram stain and culture Viral PCR</td>
<td>CT brain</td>
<td>MRI brain and spinal cord EEG EMG</td>
</tr>
</tbody>
</table>

CBC, complete blood count; WBC, white blood cell; CT computerized tomography; MRI, magnetic resonance imaging; EEG, electroencephalogram

Table 2. Recommended investigation in SLE patient with neurological presentation
6. Management

Once the diagnosis of NPSLE is confirmed the treatment will include treatment of potential aggravating factors, symptomatic treatment for the events and more specific treatment related to SLE itself.

In some condition symptomatic treatment will be required first before specific therapy is indicated. For example in patient presenting with seizure after excluding secondary causes starting antiepileptic is required before the decision on specific treatment is made (Hanly & Harrison, 2005).

The severity and the nature of neurological events will also play a role in the decision on treatment. For example patient with non-serious headache will require only symptomatic treatment.

In the presence of severe neurological disease the European League Against Rheumatism (EULAR, 2010) recommends the use corticosteroid alone or with cyclophosphamide. A Cochrane review of cyclophosphamid versus methylprednisolone in treatment of NPSLE did not find a randomised clinical trial comparing the two.

When patient failed to respond to conventional treatment or in the presence of severe disease multiple reports suggested the addition of other treatment modalities can be effective. Those include plasma exchange, rituximab or intravenous immunoglobulin.

The combination of the treatment modalities (cyclophosphmaide/corticosteroid/plasma exchange (Bartolucci et al., 2007) or plasmapheresis alone or with cyclophosphamide (Neuwelt, 2003)) was evaluated in small series of refractory disease. Results from those showed favourable outcome with combination modalities.

Rituximab is an anti-CD20 antibody that directly target B cells. Rituximab was studied in refractory cases of NPSLE and showed a rapid improvement of clinical as well radiological finding in those patients (Takunaga et al., 2006).

In the presence of thrombotic disease the management will depend whether patient had arterial versus venous thrombosis and the presence of antiphospholipid. Anticoagulation is recommended for venous thrombosis as well in the presence of arterial thrombosis with antiphospholipid antibodies. In absence of antiphospholipid antibodies and the presence of arterial thrombosis careful evaluation and management for secondary risk factors with the use of antiplatelets are indicated.

7. Common neurological disorders associated with SLE

7.1 Headache

Headache is one of the most commonly reported neurological symptoms associated with SLE. There is no specific type of headache found to have increase prevalence in patient with SLE (Mitsikostas, 2004).

When patient with SLE patient present with acute headache, special attention is warranted to rule out infection, aseptic meningitis and venous sinus thrombosis. On examination special attention is required looking for fever, meningeal signs and examination for the fundi to rule papilledema. In the presence for focal finding, papilledema or altered mental status brain imaging is required. Brain MRI with venogram is preferred to rule out venous sinus thrombosis. In presence of fever or signs of infection CSF examination is mandatory.

No specific treatment is required for nonspecific headache.
7.2 Cognitive dysfunction
It is one of the most commonly reported NPSLE syndromes. Most of the patient had mild to moderate impairment, only around 3-5% had severe impairment (EULAR, 2010). The most commonly reported abnormality is overall slowing, decrease memory, impaired working memory and executive dysfunction (Hanly, 2005).

Different report linked cognitive impairment to the presence of Apl (McLurin et al., 2005)(Denburg et al, 1997). It is also reported in patient who suffered from stroke and with Apl microinfarcts although the pattern is different between the two. Cognitive dysfunction from stroke develops acutely and remains the same in contrast to those with microinfarct as it shows stepwise deterioration. Different studies have showed a contradicting results regarding the association between global disease activity and the presence of cognitive impairment (Kozora et al., 1996)(Hay et al., 1992)(Carbotte et al., 1995). Some of the studies found an association and other did not found any association. The use of glucocorticoid associated with cognitive impairment in middle age patients irrespective of disease activity (McLurin et al., 2005). The effect of prednisone use was not significant for young and old patients.

Other causes can alter the cognitive function. Of those the development of mood disorders are particularly important. It is very well known that depression worsen cognitive function and even cause a pseudodementia. Patients with SLE also under psychological stress from the disease itself or from medications and that also can alter cognitive function even in absence of psychiatric disease (Hanly, 2005).

Formal neuropsychological testing is required to diagnose cognitive dysfunction. The main limitation of formal neuropsychological testing is time consuming and it need to be administered by an expert. The minimental test is not a good tool for screening for cognitive impairment.

MRI is indicated if the patient is less than 60 years, rapid and unexplained moderate to severe impairment, recent and significant head trauma, presence of other neurological symptoms or signs and the development of it in the setting of immunosuppressive therapy or antiplatelets (EULAR, 2010).

Patient should be screened and treated for potential precipitating factors such as metabolic and endocrine abnormalities. Associated psychiatric disorders should be treated. Control of cardiovascular risk factors also is recommended. McLurine in 2005 reported a beneficial effect of regular aspirin use on cognitive function in elderly patient with other vascular risk factors particularly in diabetics (McLurin et al., 2005).

The use of glucocorticoid with or without immunosuppressive will be considered in the presence of SLE disease activity or other NPSLE events.

Memantine is a drug used to treat dementia. One randomized clinical trial looked at the use of memantine to treat patient with SLE and cognitive impairment. No significant improvement in cognitive function in the treated group. At current the use of memantine for SLE patient with cognitive impairment is not recommended. Further clinical trial is needed (Petri et al., 2011).

7.3 Cerebrovascular disease
SLE patients are at high risk of developing vascular complications. Among those are stroke and transit ischemic attacks. Multiple causes can lead to strokes in SLE patients. The most frequent cause is atherosclerotic diseases. Other rare causes include embolic strokes from Libman Sacks endocarditis and cerebral vasculitis.
In study of carotid ultrasound in asymptomatic SLE patients, carotid plaques were seen in 25-40% of patients. Different risk factors were associated with the development of strokes in SLE patients. These include high disease activity, moderate to high titres of antiphospholipid antibodies, heart valve disease, hypertension, age and smoking (EULAR, 2010) (Toloza et al., 2004) (Bessant et al., 2004) (Futrell & Millikan, 1988). Evaluation of stroke/TIA patient will be the same as non SLE patient. Thrombolytic therapy can be given unless there are contraindications. Patients should be screened for cardiovascular risk factors and have aggressive measures to control them. Further management will include the use of antiplatelet and carotid endarterectomy if indicated. Patients who fill the criteria of antiphospholipid syndromes chronic anticoagulant therapy is indicated with a target INR of 2-3 (EULAR, 2010) (Crowther et al., 2003) (Finazzi et al., 2005).

7.4 Seizure
Seizure in SLE patient can be attributed to the disease activity or it could be related to secondary causes. The secondary causes of seizure in SLE patients are: infection, electrolyte abnormalities, uremia, hypertension, medication side effect or hypoxia. It also can be a presentation of unrelated condition such as brain tumours.

The reported prevalence of seizure is between 7.5% to 14% (Hanly et al., 2010) (Mikdashi et al., 2005) (Appenzeller et al., 2004). Seizure present at disease onset in 31.7% of patients (Mucal & Brey, 2010), and most frequently occurred within 5 years from diagnosis. Most of the patient 88.3% had single events and around 11.7% had epilepsy. The most frequently reported seizure type is generalized tonic clonic seizure followed by complex partial seizure.

Seizure can present as the only NP syndrome or accompany other neurological events mainly ischemic or hemorrhagic strokes and psychosis. Multiple studies confirmed the relation between seizure and the presence of Apl (Mikdashi et al., 2005) (Appenzeller et al., 2004) (Gibbs & Husain, 2002) (Herranza et al., 1994) (Liou et al., 1996). Also the presence of Apl were associated with shorter time to seizure occurrence (Andrade et al., 2008). Seizure occurrence is related to high disease activity, severe organ damage in particular nephritis and the presence of Apl. Factors associated with epilepsy are the same as those associated with seizure. Patients who had epilepsy are more likely to be men (Mikdashi et al., 2005) and more likely to have abnormal MRI and EEG.

The most frequent abnormality reported in brain MRI in patient with seizure is global atrophy and the presence of multiple subcortical hyperintense lesions. The most frequent EEG finding is diffuse slowing. The presence of interictal epileptic activity is associated with high recurrence rate of epileptic seizure. As most of the patients will have only one seizure, treatment with antiepileptic is not recommended. The patient should be investigated with EEG, brain MRI and have Apl antibody screening. Patient who had positive test for Apl should be monitored carefully as they have high recurrence rate. In the presence of other SLE activity or flare treatment with glucocorticoid with or without immunosuppressive is recommended (EULAR, 2010).

7.5 Acute confusional state
It is a condition characterized by acute onset of altered mental state with decrease attention. A careful exclusion of secondary causes such as metabolic, infection and side effect of medications is mandatory. CSF examination is required to exclude infection. Brain imaging is indicated to rule out structural lesions. EEG is also indicated to rule out seizure disorders.

www.intechopen.com
Treatment includes symptomatic treatment with antipsychotics to control agitation, glucocorticoid and immunosuppressive agents.

7.6 Myelopathy

Patient with SLE may present with symptoms and signs of spinal cord dysfunction which may indicate the presence of myelitis. Myelitis is less commonly reported than other NPSLE syndromes (1-3% of patient) (Lukjanowicz & Brzosko, 2009). Most commonly patient will present with acute transverse myelitis and less commonly will have longitudinal myelitis.

Acute transverse myelitis involves less than 4 segments of the spinal cord in contrast to longitudinal myelitis which involve more than 4 segments of the cord. The thoracic cord is the most commonly affected followed by the cervical cord (D'Cruz et al., 2004). Around 73% of SLE patient presenting with myelitis were positive for apl (D'Cruz et al., 2004).

Patient with myelitis present acutely with motor weakness and sensory symptoms. The extent of the symptoms depends on the level of the lesion and the extent of the inflammatory changes. Bladder and bowel dysfunction is seen in all patients with myelitis. Lupus myelitis is usually developed in the first 5 years after disease onset (Kovacs et al., 2000) (Chan & Boey, 1996). One third of the cases have another major NPSLE (EULAR, 2010). In 21-48% of patients will have associated optic neuritis (Kovacs et al., 2000) (Chan & Boey, 1996). The recurrence rate for myelitis is seen in 21-55% of patients (Kovacs et al., 2000) (Chan & Boey, 1996) (Lehnhardt et al., 2006).

When patient with SLE present with feature of myelopathy a careful exclusion of other causes of myelopathy is necessary before attributing the presentation to SLE. A contrast enhanced MRI of spinal cord is mandatory to rule out mass lesions as a cause for myelopathy. The most frequently reported abnormalities is T2 hyperintensities which become more pronounced after contrast (Lukjanowicz & Brzosko, 2009) (Provenzale et al., 1994) (Boumpas et al., 1990) (Salmaggi et al., 1994). In a group of patients the initial MRI can be normal especially if it was done early. If the initial MRI is normal repeat study in 2-7 days after onset is recommended (Lukjanowicz & Brzosko, 2009). Brain MRI is indicated when there is associated neurological symptoms and to help differentiating it from multiple sclerosis.

Cerebrospinal fluid examination is recommended to rule out infectious aetiology (EULAR, 2010). In 50-70% of cases mild CSF abnormalities are seen including mild lymphocytosis and elevated protein with normal glucose. An inflammatory CSF with granulocytes pleocytosis, elevated protein and low glucose is reported with lupus myelitis especially with longitudinal myelitis. In the presence of this finding a careful exclusion of infectious cause is mandatory. In the presence of longitudinal myelitis and associated optic neuritis serum should be send for anti neuromyelitis antibodies (anti-NMO IgG) to rule out the presence of neuromyelitis optica. Anti NMO IgG is a highly sensitive and specific antibody that target aquaporin 4 the main water channel in the CNS.

An aggressive treatment with immunosuppressive is recommended in a setting of ATM. The presence of inflammatory CSF should not delay the start of immunosuppressive. In that case a combined treatment of antimicrobial with immunosuppressive is recommended waiting for the culture results. Antimicrobial should be discontinued once infection is ruled out.
Treatment with intravenous steroid should be initiated followed by cyclophosphamide with oral steroid. The treatment should be initiated early in the disease course. Plasmapheresis has been used with immunosuppressive medication in severe cases in particular in patient with of longitudinal myelitis (D’Cruz et al., 2004). Although an earlier reports by Kovacs showed patients who had combined treatment of steroid, immunosuppressive and plasmapheresis did worse than patient who had only steroid with or without immunosuppressive (Kovacs et al., 2000). This is may be because patients who had aggressive treatments with three modalities had higher disease activity at the onset of myelitis. In the presence of Apl anticoagulant therapy is recommended with the immunosuppressive therapy. Patients with apl and Transverse myelitis who had combination therapy of immunosuppressive and anticoagulant have good functional outcome (D’Cruz et al., 2004). The functional outcome is good for patient who had early treatment. The presence of longitudinal transverse myelitis is associated with poor functional prognosis (Gertner, 2007) (Kimura et al., 2002).

### 7.7 Movement’s disorders

The most frequently reported movement disorder with SLE patient is chorea. It has been linked to antiphospholipid antibodies. Other causes of chorea such as hereditary, metabolic, endocrine causes should be excluded. Brain imaging is indicated to rule out structural causes in the presence of focal neurological signs.

Patient need to be treated symptomatically with dopamine antagonist and in severe cases the use of glucocorticoid and immunosuppressive therapy is recommended. In the presence of antiphospholipid antibodies patient need to be on antiplatelets or anticoagulants depending on the presence of other APS related symptoms. Parkinsonism is also reported in association with SLE in multiple cases. Usually it is associated with severe multisystem CNS involvements. The good response of the reported cases to immunosuppressive therapy suggests that it is a manifestation of the disease not a coincidence of Parkinson disease and SLE.

### 7.8 Peripheral nervous system Involvements

Peripheral neuropathy is the most frequent reported peripheral nervous system (PNS) involvement with SLE. The most frequent type is sensory neuropathy followed by sensorimotor neuropathy then pure motor neuropathy (Goransson et al., 2006). A subset of SLE patients may present with sensory symptoms and still have normal NCS. This is because the NCS evaluate the large myelinated fibers and the presence of normal study does not rule out small fiber neuropathy. In studies when symptomatic patients with negative NCS had skin biopsy an evidence of small fiber neuropathy was found (Goransson et al., 2006) (Omdal et al., 2002). This indicates that small fiber neuropathy is the cause of the symptomatic patients with normal NCS. Managements of peripheral neuropathy include symptomatic treatments for neuropathic pain as well glucocorticoid with or without immunosuppressive therapy depending on the severity of the disease. In the presence of severe cases, or failure of conventional treatments other modalities such as plasmaphersis, intravenous immunoglobulin and rituximab can be used. Other PNS involvements by SLE are much less. Patient may present with mononeuritis multiplex, acute demylenating polyradiculopathy, chronic demylinating polyradiculopathy
and myasthenia gravis also reported. The managements of those patients will be the same as non SLE patients.

8. Prognosis

In spite of recent advances in diagnosis and management, NPSLE remain one of the major causes of disease related morbidity. Swedish study of SLE patients did not find difference in mortality in SLE patients with or without NP. However patients with NPSLE have more functional impairments when compared to non NPSLE patients (Jonsen, 2002). Prompt diagnosis and management may played a role in reducing mortality but significant morbidity and functional incapacity still a major problem in SLE patients with neuropsychiatric symptoms.

9. Acknowledgment

The work to produce this chapter was supported by Alzaidi's Chair of research in rheumatic diseases- Umm Alqura University.

10. References


www.intechopen.com


Molloy, Calbrese. Progressive Multifocal Leukoencephalopathy. Arthritis & Rheumatism 2009;60(12):3761-3765


This book provides a comprehensive overview of the basic and clinical sciences of Systemic Lupus Erythematosus. It is suitable for basic scientists looking for detailed coverage of their areas of interest. It describes how advances in molecular biology have increased our understanding of this disease. It is a valuable clinical resource for practicing clinicians from different disciplines including rheumatologists, rheumatology fellows and residents. This book provides convenient access to information you need about cytokines, genetics, Fas pathway, toll like receptors and atherogenesis in SLE. Animal models have been reviewed as well. How to avoid delay in SLE diagnosis and management, in addition to various clinical manifestations including pregnancy and SLE have all been explained thoroughly in this book.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
